Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease (Q36428382)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease |
scientific article |
Statements
1 reference
Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease (English)
1 reference
Brian Feagan
1 reference
Stefan Schreiber
1 reference
Dorothy L Keininger
1 reference
Liz O'Neil
1 reference
CDP870 Crohn's Disease Study Group
1 reference
11 December 2007
1 reference
1 reference
289-296
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference